Dorsey Wright & Associates Invests $2.50 Million in United Therapeutics Corporation $UTHR

Dorsey Wright & Associates acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 5,128 shares of the biotechnology company’s stock, valued at approximately $2,499,000.

Several other large investors have also bought and sold shares of UTHR. Torren Management LLC bought a new stake in United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $536.59 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock has a market cap of $22.78 billion, a price-to-earnings ratio of 19.81, a PEG ratio of 1.80 and a beta of 0.57. The firm’s 50 day moving average price is $565.37 and its two-hundred day moving average price is $523.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.63 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $552.40, for a total value of $5,247,800.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,379,381.20. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.17, for a total transaction of $5,491,700.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,366,132.92. This represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 644,468 shares of company stock valued at $364,004,497. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Royal Bank Of Canada dropped their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.